Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of “Moderate Buy” from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $20.3333.

ENTA has been the subject of a number of research reports. JPMorgan Chase & Co. initiated coverage on Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 target price for the company. Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the company from $14.00 to $20.00 in a report on Wednesday, October 1st. Evercore ISI lowered their price objective on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research report on Monday, September 15th. Westpark Capital boosted their price objective on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, September 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 8th.

Insider Transactions at Enanta Pharmaceuticals

In related news, insider Yat Sun Or sold 2,390 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $34,009.70. Following the completion of the transaction, the insider directly owned 371,392 shares in the company, valued at approximately $5,284,908.16. This trade represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tara Lynn Kieffer sold 2,106 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the sale, the insider owned 30,620 shares in the company, valued at $435,722.60. The trade was a 6.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 11,961 shares of company stock valued at $170,149 over the last three months. Company insiders own 13.89% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio increased its stake in Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 1,383 shares during the last quarter. AlphaQuest LLC raised its holdings in Enanta Pharmaceuticals by 18.1% during the third quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 1,562 shares in the last quarter. Sio Capital Management LLC boosted its position in Enanta Pharmaceuticals by 1.0% during the second quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company’s stock valued at $1,352,000 after purchasing an additional 1,770 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Enanta Pharmaceuticals by 13.4% in the third quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock valued at $197,000 after purchasing an additional 1,940 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Trading Down 3.2%

Shares of Enanta Pharmaceuticals stock opened at $15.90 on Wednesday. The stock’s fifty day simple moving average is $13.23 and its 200 day simple moving average is $10.11. The company has a market capitalization of $458.87 million, a PE ratio of -4.15 and a beta of 0.96. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.26. The company had revenue of $15.13 million during the quarter, compared to the consensus estimate of $15.60 million. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%. Analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.